Business Context and Reporting Period
This Form 8-K is filed by Tocagen Inc. (not Forte Biosciences, Inc.) on August 8, 2019. The report announces the financial results for the second quarter ended June 30, 2019. The company is an emerging growth company with common stock (TOCA) listed on the Nasdaq Global Select Market.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the attached press release (Exhibit 99.1), which is referenced but not included in the provided text.
Material Changes
The filing text does not disclose specific material changes versus the prior comparable period. It serves solely as a notification that the Q2 2019 results have been issued via a press release.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, risks, contingencies, or unusual items. The document explicitly states that the information in Item 2.02 and the attached exhibit is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the correct registrant name is Tocagen Inc., as the request metadata incorrectly listed Forte Biosciences, Inc.
- Review Exhibit 99.1 (the press release) for actual financial figures, as they are absent from the 8-K body text.
- Confirm the reporting period is the quarter ended June 30, 2019.
- Note that the financial data in the press release is furnished information and not incorporated by reference into this specific filing.